Josue E Pineda
Overview
Explore the profile of Josue E Pineda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keshari S, Shavkunov A, Miao Q, Saha A, Minowa T, Molgora M, et al.
Cell Rep
. 2024 Oct;
43(11):114875.
PMID: 39446585
The goal of therapeutic cancer vaccines and immune checkpoint therapy (ICT) is to promote T cells with anti-tumor capabilities. Here, we compared mutant neoantigen (neoAg) peptide-based vaccines with ICT in...
2.
Patel B, Zhou Y, Babcock R, Ma F, Zal M, Kumar D, et al.
Leukemia
. 2024 Mar;
38(5):1143-1155.
PMID: 38467768
Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3-deficiency in...
3.
Keshari S, Shavkunov A, Miao Q, Saha A, Williams C, Highsmith A, et al.
bioRxiv
. 2024 Jan;
PMID: 38187708
The goal of therapeutic cancer vaccines and immune checkpoint therapy (ICT) is to eliminate cancer by expanding and/or sustaining T cells with anti-tumor capabilities. However, whether cancer vaccines and ICT...
4.
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
Patel B, Zhou Y, Babcock R, Ma F, Zal M, Kumar D, et al.
bioRxiv
. 2023 Feb;
PMID: 36798265
STAT3 function in hematopoietic stem and progenitor cells (HSPCs) has been difficult to discern as deficiency in the hematopoietic system induces systemic inflammation, which can impact HSPC activity. To address...
5.
Zhou Y, Medik Y, Patel B, Zamler D, Chen S, Chapman T, et al.
J Exp Med
. 2022 Nov;
220(2).
PMID: 36367776
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by immune-related adverse events (irAEs). Limited understanding of irAE mechanisms hampers...
6.
Salmon A, Shavkunov A, Miao Q, Jarjour N, Keshari S, Esaulova E, et al.
Cancer Immunol Res
. 2022 Feb;
10(5):597-611.
PMID: 35181783
Immune checkpoint therapy (ICT) using antibody blockade of programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can provoke T cell-dependent antitumor activity that generates durable clinical...